The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 09, 2010
Filed:
Aug. 31, 2004
David J. Unett, San Diego, CA (US);
Ruoping Chen, San Diego, CA (US);
Jeremy G. Richman, San Diego, CA (US);
Daniel T. Connolly, Solana Beach, CA (US);
Huong T. Dang, San Diego, CA (US);
Bryan J. Choi, Bonita, CA (US);
James N. Leonard, San Diego, CA (US);
Yaron Hakak, San Diego, CA (US);
Chen W. Liaw, San Diego, CA (US);
Dominic P. Behan, San Diego, CA (US);
Derek T. Chalmers, Cardiff, CA (US);
Michael R. Lerner, Rancho Santa Fe, CA (US);
Kevin P. Lowitz, Sunnyvale, CA (US);
David J. Unett, San Diego, CA (US);
Ruoping Chen, San Diego, CA (US);
Jeremy G. Richman, San Diego, CA (US);
Daniel T. Connolly, Solana Beach, CA (US);
Huong T. Dang, San Diego, CA (US);
Bryan J. Choi, Bonita, CA (US);
James N. Leonard, San Diego, CA (US);
Yaron Hakak, San Diego, CA (US);
Chen W. Liaw, San Diego, CA (US);
Dominic P. Behan, San Diego, CA (US);
Derek T. Chalmers, Cardiff, CA (US);
Michael R. Lerner, Rancho Santa Fe, CA (US);
Kevin P. Lowitz, Sunnyvale, CA (US);
Arena Pharmaceuticals, Inc., San Diego, CA (US);
Abstract
The present invention relates to methods of identifying whether a candidate compound is a modulator of a G protein-coupled receptor (GPCR). In preferred embodiments, the GPCR is human. In other preferred embodiments, the GPCR is coupled to Gi and lowers the level of intracellular cAMP. In other preferred embodiments, the GPCR is expressed endogenously by adipocytes. In further preferred embodiments, the GPCR inhibits intracellular lipolysis. In other further preferred embodiments, the GPCR is a nicotinic acid receptor. The present invention also relates to methods of using a modulator of said GPCR. Preferred modulator is agonist. Agonists of the invention are useful as therapeutic agents for the prevention or treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, stroke, insulin resistance, and type 2 diabetes.